PLYM17034 / ANHL1522 / Angela Girvin
Basic Study Information
Purpose:Location: University of Rochester
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific
T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive,
cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder.
Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells
to grow and spread. LMP-specific T-cells are special immune system cells trained to
recognize proteins found on post-transplant lymphoproliferative disorder tumor cells
if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells
may work better in treating pediatric organ recipients with post-transplant lymphoproliferative
disorder than rituximab alone.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search